Roche/PTC edge closer to disrupting market for SMA rivals Biogen and Novartis with more positive data
Roche and partner PTC Therapeutics have broken out detailed positive data backing their spinal muscular atrophy therapy, which is expected to have a good shot at eclipsing Spinraza’s market leadership.
The FDA is set to make its decision on the therapy, risdiplam, by May 24. If approved — the drug is expected to generate between $2 billion and $3 billion in peak sales — and compete with Biogen’s first-to-market Spinraza and Novartis’ most-expensive-drug-in-the-world Zolgensma.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.